TABLE 2.
Evaluation of treatment response
| No. | Treatment | MRI | PET |
|---|---|---|---|
| 1 | 1× HDMTX | ND (death) | ND (death) |
| 2 | 6× HDMTX | PR | No pathologic uptake |
| 3 | 6× HDMTX + Ifosfamide | CR (cerebral) after 3 cycles, CR (thoracic) after 6 cycles | No pathologic uptake in the brain after 3 cycles, No pathologic uptake in the chest after 6 cycles |
| 4 | 5× HDMTX | CR | No pathologic uptake |
| 5 | 6× HDMTX | CR | No pathologic uptake |
| 6 | 2× HDMTX | PD | Increase of pathologic uptake in 1 of 3 lesions |
| 7 | 2× HDMTX | PR | Pathologic uptake reduced |
| 8 | 6× HDMTX | SD/MR | No pathologic uptake |
| 9 | Ibritumomab tiuxetan | SD | Persistant pathologic uptake |
| 10 | Ibritumomab tiuxetan | PD | ND |
PET = positron emission tomography; HDMTX = high-dose methotrexate; ND = not done; PR = partial response; CR = complete response; PD = progressive disease; SD = stable disease; MR = minimal response